Sana Biotechnology Inc (NASDAQ: SANA)’s stock price has decreased by -1.75 compared to its previous closing price of 1.71. However, the company has seen a -30.58% decrease in its stock price over the last five trading sessions. accessnewswire.com reported 2025-03-31 that NEW YORK, NY / ACCESS Newswire / March 31, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=140048&wire=1 or contact Joseph E. Levi, Esq.
Is It Worth Investing in Sana Biotechnology Inc (NASDAQ: SANA) Right Now?
The 36-month beta value for SANA is also noteworthy at 1.78. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for SANA is 125.16M, and at present, short sellers hold a 31.87% of that float. The average trading volume of SANA on April 01, 2025 was 7.53M shares.
SANA’s Market Performance
SANA’s stock has seen a -30.58% decrease for the week, with a -35.63% drop in the past month and a -1.18% fall in the past quarter. The volatility ratio for the week is 12.94%, and the volatility levels for the past 30 days are at 11.17% for Sana Biotechnology Inc The simple moving average for the last 20 days is -29.40% for SANA stock, with a simple moving average of -56.04% for the last 200 days.
Analysts’ Opinion of SANA
Many brokerage firms have already submitted their reports for SANA stocks, with Citizens JMP repeating the rating for SANA by listing it as a “Mkt Outperform.” The predicted price for SANA in the upcoming period, according to Citizens JMP is $5 based on the research report published on March 18, 2025 of the current year 2025.
Jefferies, on the other hand, stated in their research note that they expect to see SANA reach a price target of $7. The rating they have provided for SANA stocks is “Buy” according to the report published on March 14th, 2025.
SANA Trading at -39.47% from the 50-Day Moving Average
After a stumble in the market that brought SANA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.00% of loss for the given period.
Volatility was left at 11.17%, however, over the last 30 days, the volatility rate increased by 12.94%, as shares sank -30.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -48.31% lower at present.
During the last 5 trading sessions, SANA fell by -30.58%, which changed the moving average for the period of 200-days by -75.62% in comparison to the 20-day moving average, which settled at $2.3795. In addition, Sana Biotechnology Inc saw 3.07% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SANA starting from CHRISTIAN HORDO & KATHARINE HO, who proposed sale 75,000 shares at the price of $3.16 back on Feb 18 ’25. After this action, CHRISTIAN HORDO & KATHARINE HO now owns shares of Sana Biotechnology Inc, valued at $237,000 using the latest closing price.
CHRISTIAN HORDO & KATHARINE HO, the Officer of Sana Biotechnology Inc, proposed sale 75,000 shares at $3.86 during a trade that took place back on Jan 16 ’25, which means that CHRISTIAN HORDO & KATHARINE HO is holding shares at $289,500 based on the most recent closing price.
Stock Fundamentals for SANA
The total capital return value is set at -0.59. Equity return is now at value -99.17, with -50.03 for asset returns.
Based on Sana Biotechnology Inc (SANA), the company’s capital structure generated 0.27 points at debt to capital in total, while cash flow to debt ratio is standing at -2.37.
Currently, EBITDA for the company is -272.72 million with net debt to EBITDA at 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.54.
Conclusion
In summary, Sana Biotechnology Inc (SANA) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
